News

Capsugel claimed that its France facility Ploermel provides clinical trial and commercial pharmaceutical product manufacturing services to customers around the world. The FDA’s Pre-Approval and Good Manufacturing Practices

Takeda’s wholly-owned subsidiary Takeda San Diego has developed Nesina, a dipeptidyl peptidase-IV (DPP-4) inhibitor, which exhibits high selectivity for DPP-4 inhibition, and a once daily dosing of the

The trial, called Explore, is expected to evaluate the safety and tolerability of BG-12 when administered with beta interferons (IFNß) or glatiramer acetate (GA) to patients who continue

Pfizer’s ‘Rare Disease Research Unit’ is expected to pursue treatments across all therapeutic areas and modalities and will serve as the focal point for the company’s existing research

Urocell is based on an innovative therapy concept for the treatment of bladder weakness, aimed at people with damaged sphincters. Urocell is based on the principle of the

UCB said that Vimpat is available in three formulations, oral tablets, oral solution and IV injection, ensuring that patients can maintain consistent Vimpat treatment in any clinical setting.

Almac Pharma Services said that the new facility includes dispensing and blending suites to accommodate 2.5 tonne batches, coupled to a sachet filling and packaging line. The new

UBC is a US-based global scientific and medical affairs organisation that partners with life science companies to develop and commercialise biopharmaceuticals, medical devices, and other health care products,

GSK said that the FDA approval for the combination was based on the results from a two-year study CombAT (Combination of Avodart and Tamsulosin), an international multicenter, randomised,